Macquarie described Neuren Pharmaceuticals shares as a standout in the biotech industry and set a price target of $18.60 on ...

In morning trade, the ASX 200 uranium stock is up 2% to $4.57. This leaves it just short of its 52-week high of $4.63.

This ASX 300 stock is having a good session on Wednesday. Let's see why investors are bidding its shares higher ...

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor ...

Analysts from Morgan Stanley believe the humanoid robot market could be worth $5 trillion by 2035. Musk believes Tesla could ...

Aurizon Holdings has struck a new deal with materials giant BHP. Macquarie believes this is good news for Aurizon shares.

Citi currently has a buy rating and $2.70 price target on its shares. Another ASX dividend stock that has been given a buy ...

These 2 ASX growth shares could deliver big returns, in my opinion. Here’s why I’m excited about them right now.

The ASX dividend share is one of the leaders in the sector, in my opinion. It's expecting to pay a distribution per security ...

Bell Potter currently has a buy rating on the ASX tech share with a $122.50 price target. Based on its current share price of ...

The Vanguard Australian Shares Index ETF (ASX: VAS) is a very popular investment. But, there are other attractive ASX ETFs to ...